Hero Background


Discover, design, and deliver the right drug for the right patient

Tempus provides integrated solutions to help meet your needs from early discovery through commercialization.


We partner with scientists and researchers to accelerate the drug development process

  • 2/3

    of the top 20 pharma oncology companies partner with Tempus

  • 140+

    biopharma partnerships

Our Differentiators

Data Collaborations

  • 5.5M+

    de-identified research records to power scientific discovery to improve patient outcomes

  • 600K+

    records with matched clinical data linked with genomic information to understand driver mutations and outcomes associations

  • 100K+

    records with full transcriptomic data for interrogating tumor biology and mechanisms of action


  • 6

    NGS tests to support clinical trial and research sequencing

  • 5K+

    oncologists rely on Tempus as their precision medicine partner

Clinical Trial Solutions

  • 8.8

    days on average to activate a new site (between April 2020–August 2021)

  • 200+

    provider networks and research institutions in the TIME Trial® Program

  • 16K+

    patients were identified for potential enrollment into clinical trials in our network

Our Impact

Thanks to Tempus, we are able to identify patients that can be helped with our proprietary TMod™ platform. Without them, we wouldn’t be able to do this.

William Go, SVP, Head of Development at A2 Biotherapeutics (TMod™ is a trademark of A2 Biotherapeutics)

Our Impact

Tempus is a leader in the field of personalized medicine, and like Genmab, Tempus has a mission to improve the lives of cancer patients. We are looking forward to expanding our exciting partnership with them and to the possibility of discovering important new oncology targets and biomarkers.

Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab

Learn more about our partnership with Genmab
Our Impact

Bayer’s strong focus in precision medicine combined with Tempus’ unique testing offering has culminated in this collaboration to bring genomic testing to cancer patients.

Bhavesh Ashar, Senior Vice President, Head of U.S. Oncology at Bayer

Learn more about our partnership with Bayer
Our Impact

Our partnership with Tempus will enable us to collect important retrospective information about the patients enrolled in the dose escalation part of our clinical trial that we can potentially use to inform enrollment in the expansion stage of our study.

Jorge DiMartino, Chief Medical Officer and Executive Vice President, Clinical Development at Kronos Bio

Learn more about our partnership with Kronos

Tempus empowers you to make smarter, faster, and more efficient decisions

Get customized solutions for your needs.